Status:
NOT_YET_RECRUITING
Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Lead Sponsor:
Changhai Hospital
Collaborating Sponsors:
Affiliated Hospital of Jiangnan University
The Affiliated People's Hospital of Ningbo University
Conditions:
Pronase
Mucosal Clarity
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Pronase is a proteolytic enzyme known for its ability to clear mucus by breaking down its main component, mucin, through enzymatic hydrolysis. This property makes it useful in gastroscopy, where it is...
Eligibility Criteria
Inclusion
- Patients presenting with intestinal inflammation during colonoscopy, accompanied by mucus obscuring visualization, were included, particularly those with inflammatory bowel disease (IBD), regardless of the presence or absence of clinical symptoms such as abdominal pain, diarrhea, hematochezia, or mucoid stools.
- Researchers assessed the current health status of potential participants to ensure they could tolerate colonoscopy (based on physical examination and medical history).
- Age range was 18-75 years (inclusive).
- Participants provided written informed consent to participate voluntarily.
Exclusion
- Participants with known hypersensitivity or allergy to the study medication.
- Participants with peritonitis, intestinal obstruction, severe intestinal infection, or radiation colitis.
- Participants who did not exhibit intestinal mucus obscuring endoscopic visualization during colonoscopy.
- Participants with severe cardiovascular, pulmonary, neurological, or renal disease, or those deemed unfit for colonoscopy.
- Participants who did not provide written informed consent or lacked the capacity to do so.
- Pregnant or breastfeeding women.
- Participants who had taken antiplatelet medications (e.g., aspirin, clopidogrel) or had abnormal coagulation function within 7 days prior to colonoscopy.
- Participants currently participating in other clinical observation trials or who had participated in another clinical trial within 60 days.
Key Trial Info
Start Date :
March 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
438 Patients enrolled
Trial Details
Trial ID
NCT06874673
Start Date
March 17 2025
End Date
November 30 2025
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai Hospital, Naval Medical University
Shanghai, Shanghai Municipality, China, 200433